Compare SHC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | ACAD |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | 2020 | 2004 |
| Metric | SHC | ACAD |
|---|---|---|
| Price | $17.14 | $27.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | $17.80 | ★ $29.39 |
| AVG Volume (30 Days) | ★ 2.5M | 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | 0.20 | ★ 1.54 |
| Revenue | ★ $1,150,379,000.00 | $1,047,118,000.00 |
| Revenue This Year | $6.41 | $15.16 |
| Revenue Next Year | $5.89 | $11.42 |
| P/E Ratio | $87.90 | ★ $17.62 |
| Revenue Growth | 2.67 | ★ 12.69 |
| 52 Week Low | $9.53 | $13.40 |
| 52 Week High | $17.78 | $27.73 |
| Indicator | SHC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 66.31 |
| Support Level | $16.55 | $26.60 |
| Resistance Level | $17.00 | $27.47 |
| Average True Range (ATR) | 0.34 | 0.84 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 73.44 | 86.16 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.